Reply to: an assessment of the cytochrome P450 2-hydroxyisoflavanone synthase (2-HIS) crystal structure. [PDF]
Wang X, Pan H, Sagurthi SR, Dixon RA.
europepmc +1 more source
Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants. [PDF]
Kim JD +4 more
europepmc +1 more source
In Vitro Cytochrome P450 Interaction Profile and ADME Characterisation of Gold(I)-Triphenylphosphine Complexes with 6-Alkoxy-9-deazapurine Ligands. [PDF]
Medvedíková M +3 more
europepmc +1 more source
Genotype-Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers. [PDF]
Etkins J +11 more
europepmc +1 more source
Associations between antihypertensive drug-related gene polymorphisms and cardiovascular outcomes in hypertensive patients: a gene-drug interaction study. [PDF]
Li Z +8 more
europepmc +1 more source
Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates. [PDF]
D'Cunha R +8 more
europepmc +1 more source
Self-Reported Pharmacogenetic Medication Use in the Our Future Health Cohort. [PDF]
Dixon P +4 more
europepmc +1 more source
Hypertension pharmacogenetics and limitations in Africa - a focus on the ACE, AGTR1 and CYP2C9 genes. [PDF]
Gomera RT +4 more
europepmc +1 more source
Assessing the influence of CYP2C9 and CYP2C19 genotypes on the metabolism of CBD-cannabis after controlled single and repetitive consumption. [PDF]
Schulte J +8 more
europepmc +1 more source
Genetic Variants Associated with Non-Steroidal Anti-Inflammatory Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. [PDF]
Kosanlawit J +7 more
europepmc +1 more source

